Innovation
-
The Johnson & Johnson Institute helps HCPs learn new surgery skills—here’s how
From suturing to robotics system training, the Johnson & Johnson Institute is bringing surgical education to busy HCPs so they can deliver safe, effective care.
-
“Reimagining what life with schizophrenia could look like”
Johnson & Johnson’s Leonardo Diaz, M.D., addresses common misconceptions about schizophrenia, the critical importance of preventing relapse and why there’s so much optimism about treatments. -
“We are in a golden age of cataract surgery”
Once considered a straightforward procedure to restore cloudy vision, cataract surgery has evolved into one of the most technologically advanced—and personalized—operations in modern medicine. Learn how Johnson & Johnson’s 25-year history of innovation is helping eye surgeons meet the moment. -
5 ways Johnson & Johnson is innovating in medicines and therapies
From rare diseases to all-too-common cancers, Johnson & Johnson is on a mission to improve treatment options for people around the globe. Learn more about how the company is working to create new therapies for IBD, lung cancer, major depressive disorder, bladder cancer, myasthenia gravis and more.
Featured stories
-
How the Polyphonic™ AI Fund for Surgery QuickFire Challenge awardees are aiming to empower surgeons
Johnson & Johnson launched this competition with one goal: to accelerate the development of next-generation surgical technologies. Meet this year’s three awardees and learn about their innovations. -
5 things we now know about plaque psoriasis
Plaque psoriasis is the most prevalent form of psoriasis, affecting millions worldwide. Johnson & Johnson is focused on developing novel therapies for chronic dermatologic diseases to address the unmet need that still exists.
-
Striving for a cure for multiple myeloma: What HCPs need to know
Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer. -
5 things we now know about atrial fibrillation
More than 50 million people worldwide are affected by this common type of heart arrhythmia. Learn the facts behind this heart condition, plus one patient’s diagnosis story. -
Moving toward a more personalized approach to treating depression
The World Health Organization predicts that depression will be the leading cause of disability across the globe by 2030. Learn how Johnson & Johnson is on a mission to change that.
